anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Numerous natural bioactive compounds extracted from Chinese medicines have been proved to be promising and potent agents in the treatment of ischemic stroke. Hydroxysafflor yellow A (HSYA), separated from Carthamus tinctorius, has increasingly attracted attention for its broad spectrum of pharmacological effects, especially of its neuroprotective action. Our previous studies revealed that HSYA plays significant beneficial roles in a dose-dependent manner in rats with focal cerebral ischemia. However, treatment with higher doses of HSYA appeared to bring about adverse reactions in the rats. In present study, we adopted tenuigenin (TEN), extracted from the Polygala tenuifolia root, in combination with HSYA to optimize the therapeutic strategy against ischemic stroke, and further explored the underlying mechanisms of action of the combination in vivo and in vitro. We firstly confirmed the pharmacological efficacies of co-treatment of HSYA and TEN in middle cerebral ischemia occlusion (MCAO) rats and observed the synergistic improvement of infarct volume, cerebral edema, and morphology of neuron cell body. Behavioral experiments indicated that combination of HSYA and TEN could synergistically improve motor and cognitive function in MCAO rats. We also observed increased viability and suppressed cell apoptosis after HSYA and TEN co-treatments in the oxygen-glucose deprivation/reperfusion (OGD/R) SH-SY5Y cells. Furthermore, JAK2/STAT3 and SOCS3 signaling interaction was demonstrated to be a critical responsor to the co-treatment of HSYA and TEN. In the subsequent experiments with silencing SOCS3 in OGD/R-exposed cells, we found that HSYA and TEN might suppress JAK2/STAT3 pathway through different regulatory mechanisms targeting SOCS3-negative feedback signaling. HSYA seemed to impose excessive activation of JAK2/STAT3 to trigger SOCS3-negative feedback signaling, while TEN appeared to provoke SOCS3 inhibitory feedback role directly to further attenuate JAK2-mediated signaling. Collectively, HSYA and TEN might modulate the crosstalk between JAK2/STAT3 and SOCS3 signaling pathways in different manners that eventually contributed to their synergistic therapeutic effects against cerebral ischemic stroke.
Using a prospective observational design, this study investigated the hypothesis that competing in the Suffolk Back Yard Ultra-marathon, would result in impaired cognitive performance and examined whether pre-race sleep patterns could mitigate this. Fifteen runners (1 female) volunteered to undertake this study and eleven males were included in the final analysis. Before the race and after withdrawal participants completed the following cognitive performance tasks: 2 Choice Reaction Time (2CRT), Stroop, and the Tower Puzzle. Pre-race sleep strategies were subjectively recorded with a 7-day sleep diary. Following race withdrawal, reaction time increased (Δ 77±68 ms; p = 0.004) in the 2CRT and executive function was impaired in the Stroop task (Interference score Δ -4.3±5.6 a.u.; p = 0.028). Decision making was not affected in the Tower Puzzle task. There was a significant correlation between the pre-race 7-day average sleep scores and both 2CRT Δ throughput (r = 0.61; p = 0.045) and 2CRT Δ RT (r = -0.64; p = 0.034). This study supports the hypothesis that running an ultra-marathon, which includes at least one night of sleep deprivation, impairs cognitive performance and provides novel evidence suggesting good sleep quality, in the week prior to an ultra-marathon, could minimise these effects.
The invention provides a medical image three-dimensional reconstruction simulation method and system, and relates to the technical field of medical images. The method comprises the following steps: the two-dimensional image is pre-processed to determine a closed contour of the two-dimensional image. And carrying out volume reconstruction on the two-dimensional image according to the closed contour line to obtain a volume reconstruction result. And carrying out image segmentation on the two-dimensional image by adopting an image segmentation algorithm to obtain a plurality of sub-images, and extracting the image characteristics of the sub-images by utilizing a characteristic extraction algorithm. And performing surface reconstruction on the two-dimensional image by using the two-dimensional parallel contour line to obtain a surface reconstruction result. And performing three-dimensional reconstruction on the two-dimensional image according to the volume reconstruction result and the surface reconstruction result to obtain a three-dimensional image. The volume reconstruction result can accurately reflect the body type of the target part, and the surface reconstruction result can accurately reflect the detail characteristic points of the target part, so that the accuracy of the constructed three-dimensional image is ensured, and the misdiagnosis caused by the inaccuracy of the three-dimensional image is avoided.
Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment is a sterile antimicrobial ointment for ophthalmic use. 

Bacitracin zinc is the zinc salt of bacitracin, a mixture of related cyclic polypeptides (mainly bacitracin A) produced by the growth of an organism of the licheniformis group of Bacillus subtilis var Tracy. It has a potency of not less than 40 bacitracin units per mg. The structural formula for bacitracin A is: 

Polymyxin B Sulfate is the sulfate salt of polymyxin B1 and B2 which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formulae are: 

Each gram contains: Bacitracin zinc equal to 500 bacitracin units and polymyxin B sulfate equal to 10,000 polymyxin B units, white petrolatum and mineral oil.
According to the present invention, anticonvulsant compounds N-acetyl, N'-benzylglycinamide and N-benzyloxycarbonylglycinamide-Z-glycinamide are disclosed. The present invention also discloses an anticonvulsant pharmaceutical composition comprising an effective amount of at least one active ingredient selected from N-acetyl, N'-benzylglycinamide and N-benzyloxycarbonylglycinamide-Z-glycinamide and pharmaceutically acceptable carrier or diluent. The present invention provides a method of controlling convulsions in a mammal by administering to the mammal an effective amount of antiepileptic compounds N-acetyl, N'-benzylglycinamide or N-benzyloxycarbonylglycinamide-Z-glycinamide. Combinations of the anticonvulsion compounds can also be administered. The convulsions may be due to epilepsy, febrile convulsions or convulsions precipitated by irritative lesions in the brain. Further the composition may be used to prevent migraine and to treat chronic pain and bipolar disorder.
The herbal medicine (Maytenus senegalensis) has been scientifically investigated for acute toxicity in vitro and antiplasmodial activity both in vitro and in vivo where it showed strong antimalarial activity. However, to our knowledge, no antimalarial studies have been performed on this herbal medicine in standardized clinical settings.

The study will contain two treatment groups. Group 1 will have 12 healthy male adults aged 18 to 45 years who will be given the malaria herbal remedy (Maytenus senegalensis) and followed up for safety for 56 days. The subgroup 1a will be the first group to be enrolled in the study and given Malaria herbal remedy. The safety assessment of this group will be done in 7 days after the first treatment. If there will be no major safety concern per-protocol among participants of group 1a, the subgroup 1b participants will be enrolled in the study and given Malaria herbal remedy. The safety assessment of this subgroup 1b will be done 7 days after the first treatment. If there will be no major safety concern per-protocol among participants of group 1b, the subgroup 1c participants will be enrolled in the study and given Malaria herbal remedy. The safety assessment of this subgroup 1c will be done 7 days after the first treatment. If there will be no major safety concern per-protocol among participants of group 1c, the subgroup 1d participants will be enrolled in the study and given Malaria herbal remedy. The decision to proceed from G1 to the enrolment of G 2 participants will be determined by pre-specified "go or no go" criteria.

Study group 2 will comprise two subgroups of male Adults aged 18 to 45 years with uncomplicated malaria. The first is study group 2a of 52 uncomplicated malaria patients who will be treated with the malaria herbal remedy (Maytenus senegalensis) while G2b of 52 uncomplicated malaria patients will be treated with Artemether-lumefantrine. Patients will be followed up for 56 days. In the presence of failure for either the herbal remedy and Artemether-lumefantrine and Early Treatment Failure criteria met, the rescue treatment will be used.

The purpose of utilizing Group 1 participants is to assess the safety and tolerability of Maytenus senegalensis and proof of the concept that the herbal product is safe for the human subject. Therefore, the decision to proceed to Group 2 intervention for patients with naturally acquired malaria will be subjected to pre-specified "go or no go" criteria. These criteria will be based on safety data obtained from the sentinel group of 12 participants on day 28 after the first treatment and will be reviewed by an independent safety monitoring committee (SMC) appointed for this study. If one of the following criteria will be met, the study will not enroll the remaining G2 participants: (i)Any SAE related to the antimalarial herbal remedy (ii) ≥50% of the participants experienced a Grade 3 AR persisting at Grade 3 for \> 48 hours during the 14 follow-up days.
OBJECTIVE: Analyze the ultrasound findings, single nucleotide polymorphism array (SNP-array) results, and pregnancy outcomes of fetuses with 7q11.23 deletions and duplications in the second and third trimesters. Investigate the prenatal ultrasound characteristics and follow up information of these fetuses.
METHODS: Seven fetuses were diagnosed with 7q11.23 deletion and six with 7q11.23 duplication via SNP-array at the prenatal diagnosis center of a single Chinese tertiary medical center from January 2017 to May 2024. Maternal demographics, ultrasound findings, SNP-array results, pregnancy outcomes, and follow-up information were comprehensively reviewed and analyzed.
RESULTS: The copy number variations (CNVs) ranged from 1.43 Mb to 1.78 Mb in cases of 7q11.23 deletions and from 1.42 Mb to 1.68 Mb in cases of 7q11.23 duplications. These CNVs encompassed 29 OMIM-listed genes, including ELN, DNAJC30, GTF2IRD1, and GTF2I. Among the seven cases of 7q11.23 deletion syndrome, six exhibited ultrasound abnormalities. The main clinical phenotypes included three cases of intrauterine growth restriction and four cases of cardiovascular system abnormalities, specifically two cases with ventricular septal defects, one case with aortic narrowing, and one case with supravalvular pulmonary stenosis. One case was particularly notable, exhibiting complex multi-organ structural malformations. Out of six cases of 7q11.23 duplication syndrome, five exhibited ultrasound abnormalities. These included two cases of cardiovascular abnormalities: one case with a widened left ventricle and another case with a shortened fetal humerus length. One case revealed complex multi-organ structural malformations, including hydronephrosis, a microgallbladder, and a cleft lip and palate. All seven cases of 7q11.23 deletions and three cases of 7q11.23 duplications opted for termination of the pregnancy. The remaining three cases of 7q11.23 duplications chose to continue the pregnancy. One case underwent surgical treatment for a ventricular septal defect after birth, and the prognosis was favorable. Another case involved a full-term delivery, this child was followed up at the age of 4 and exhibited a phenotype of poor language expression ability.
CONCLUSION: Our study broadened the clinical phenotype spectrum of fetuses with 7q11.23 deletions and duplications. Additionally, it conducted a preliminary evaluation of prenatal ultrasound findings and postnatal clinical phenotypes in follow-up cases. The clinical phenotype of fetuses with 7q11.23 deletion and duplication syndromes involves multiple systems and is relatively complex. Cardiovascular abnormalities and intrauterine growth restriction are the most common clinical manifestations observed in prenatal 7q11.23 deletion syndrome. Fetuses with 7q11.23 duplications exhibit a wide range of clinical phenotypes that lack specificity.
FIELD: veterinary medicine. SUBSTANCE: the present innovation deals with medicinal activation of specific work of smooth uterine musculature, prevention of delay and removal of delayed afterbirth, prophylaxis and therapy of postnatal endometritis. "Oxycamph" preparation is injected into ventral, dorsal lumbar muscles in animals or pararectally; this preparation contains solutions of medicinal substances at the following ratio of components, weight%: oxytocin solution containing 5 U/ml 22.6-24.2, 2%-synestrol oily solution 6.0-7.6, 20%- camphor oily solution 45.6- 47.2, 10%-lidocaine hydrochloride solution 22.6-24.2 at the dosage of 0.08- 0.13 ml/kg body weight. At treating weak tongs of smooth uterine musculature this preparation should be injected for parturient patients before the onset of labor or between contractions. In case of afterbirth delay this preparation should be injected 20- 60 min after the birth of successive offspring. In case of treating postnatal endometritis the preparation in question is injected at interval of 1-2 d for several times, but in case of uterine cavity washing at open cervix with solutions of medicinal substances recommended for this cases. The method provides combined impact onto different function in parturient patients at weak contractions of smooth uterine musculature at prolonged delivery, for the purpose to remove delayed afterbirth, to prevent the development and therapy of postnatal endometritis and improve the state of sick animal in short terms. EFFECT: higher efficiency of therapy and prophylaxis. 5 cl, 1 tbl
PROBLEM TO BE SOLVED: To provide a thiazolidinedione analogue useful for treating hypertension.SOLUTION: The present invention relates to a thiazolidinedione analogue useful for treating hypertension. In general, the present invention relates to a compound that reduces binding and activation of the nuclear transfer factor PPARγ. A compound exhibiting PPARγ activity induces transcription of genes that favor sodium re-adsorption. The compound reduces binding or activation of the nuclear transcription factor PPARγ, does not augment sodium re-absorption, and is therefore more useful in treating hypertension. Advantageously, the compound having lower PPARγ activity exhibits fewer side effects than a compound having a higher level of PPARγ activity. Most specifically, by lacking PPARγ binding and activation activity, the compound is particularly useful for treating hypertension both as a single agent and in combination with other classes of antihypertensive agents.
During the experimental day the subject will undergo a 75gr-OGTT. On the evening before the experimental day, the subject will ingest placebo tablets.
The present invention describes the development of a end-capped bipyridine compound having formula (A) and the zinc complex having formula (B). The, assay having formula (1) can be used to estimate and quantify the amount of zinc ions by monitoring the fluorescence changes. The assay with formula (1) can be use to image and detect Zn 2  ions in MCF7 cell lines. The zinc complex of formula (2) and (4) can be used as a fluorescent sensor for cyanide anions using analyte replacement protocol. The assay with formula (2) is, selective only to cyanide anions even in the presence of other competing anions. The assay with formula (3) having bright green solid state emission is used for the preparation of formula (4). The orange fluorescent powder of assay with formula (4) is used for the selective detection of CN ions in aqueous solution.
Annually, more than 250,000 patients in the U.S. with end-stage heart failure stand to benefit from ventricular assist device (VAD) therapy. Despite VADs providing long-term "durable" support, this therapy is associated with substantial risk (50% mortality at 4 years) and expense ($179,000 for inpatient services). Additionally, 60% of patients develop a healthcare-associated infection (HAI) within 90-days of implantation. Broad adoption of durable VAD therapy is hindered in part by HAIs, given associated sequelae (6-fold increased risk of 1-year mortality) and costs ($264,000 - $869,000 per patient). It is critical to determine how best to prevent HAIs in order to maximize the benefit of VAD therapy. While several studies have reported variation in HAI rates across centers after complex cardiac surgery, less is known in the setting of durable VADs. The average 90-day HAI rate after VAD implantation is as high as 19 events per 100 patient-months and varies (25th - 75th percentile, 9-23) across centers. While some argue that centers with lower HAI rates select healthier patients, others counter that improved practices (e.g., standardizing empirical and targeted antimicrobial therapy) or enhanced provider teamwork are more predictive of improved outcomes.

While evidence-based HAI prevention guidelines and implementation tools (e.g., checklists) exist, these approaches are not comprehensive (e.g., neglecting device-specific determinants) or customizable to local context, thus limiting usability, adoption, and likelihood of significant effectiveness for preventing HAIs. Understanding the barriers and facilitators within individual centers for maximizing adoption of prevention measures would serve as the foundation for targeted improvement strategies. Without this knowledge, evidence-based, action-oriented recommendations will have limited local adoption and ultimately effectiveness in preventing HAIs after VAD implantation.

The investigators long-term goal is to develop and subsequently promote wide-scale adoption of evidence-based HAI prevention practices following durable VAD implantation. The objective of this proposal is to identify prevention recommendations for the most significant HAIs after VAD implantation. To achieve this objective, the investigators will undertake a mixed methods study of adult patients receiving VADs in the U.S. from 2009 - 2017 and develop a modular toolkit of evidence-based recommendations. To determine best practices for preventing HAIs, the investigators will examine center-level differences in HAI rates to identify strategies used by centers with low rates, and potential barriers among centers with high rates.
Oral sustained release pharmaceutical forms comprise a pharmaceutically active agent dispersed in a solid matrix of a lipid which is solid at room temperature and silica having a particle size not exceeding 0.1 mm., preferably colloidal silica. Preferred lipids are cetyl or stearyl alcohol; palmitic or stearic acid; 12-hydroxy stearic acid; or hydrogenated castor - or cocoanut - oil, or may be higher esters, or mineral, vegetable or animal waxes.  The silica may be colloidal pyrogenic silica.  The compositions are prepared by melting the lipid or softening it with volatile organic solvent e.g. npropanol, adding the silica to yield a gel, dispersing the finely divided drug into the gel, congealing the latter by cooling or removing the solvent, and then grinding the composition to granules and compressing them into tablets.  The tablets may be coated with a soluble rapid release composition of a drug by conventional coating procedures.  The rate of release of drug from the sustained release composition may be regulated by inclusion therein of water-soluble substances, such as salts, glycine, urea and polyethylene glycol, or else water-soluble gums or insoluble hydrophilic fillers, to increase the rate of release, or lipid-soluble water-insoluble polymers such as ethyl cellulose, to decrease release rate.  Also the drug itself may be used in suitably modified form to achieve such effects. Examples are given for sustained release forms, which may be coated, containing methamphetamine and phenobarbital, brompheniramine maleate; hyoscine, atropine and hyoscyamine; phenylephrine, phenyl propanolamine and chlorpheniramine; quinidine; and glycopyrrolate with phenobarbital and phenobarbital sodium.  Many other drugs are listed by name.
The present invention discloses an industrial production method for antihypertensive peptides using corn germ protein as raw materials. The invention belongs to the field of food nutrition and biotechnology. The invention uses Alcalase 2.4L, papain and Dispase II to continuously digest corn germ protein, and then obtain corn antihypertensive peptide by centrifugation, ultrafiltration, concentration and spray drying processes. Among the received antihypertensive peptides, the components molecular weight less than 1000 Da accounted for more than 92% and the peptide alanine-tyrosine (Ala-Tyr, AY) accounted for more than 0.6%.; The analysis shows that the corn antihypertensive peptides have good activity in vitro ACE inhibitory as well as the stability of temperature, pH and major gastrointestinal digestive enzymes, and a significant effect to lower the blood pressure on essential hypertension rats. Production method of this invention has advantages of high biological activity, low processing costs, large processing capacity and easy for industrial production. The corn antihypertensive peptides produced in this way can be used as new functional nutrients used in food, health food and pharmaceutical development and production, and have broad market prospects.
PURPOSE:To surely correlate the corresponding image signal and ID information by attaching an identification code to a cassette or a film, and providing a reading means reading this identification code on both an ID terminal and an extraction section. CONSTITUTION:An X-ray film is photographed and recorded while kept stored in a cassette 1. The bar code 1a of the cassette 1 is read with a bar code reader 2a at the time of photographing, and the ID information such as the date of photographing is inputted to an ID terminal 2. When the cassette 1 is loaded to the cassette automatic opener 3 of an X-ray image reader 10 after X-ray photographing is completed, the bar code 1a is read with a bar code reader 3a, and the ID information and the image signal obtained by reading the radiation image recorded on the film in the cassette 1 are correlated one to one. The film is then extracted and sent to an automatic developing machine 4. The film is developed, fixed, washed with water, and dried, then it is sent to a film digitizer 5. The analog image signal is converted into a digital image signal S. corresponding to the whole X-ray image, and it is stored in a photo- disk 12 while correlated with the ID information.
Women with early and late preterm pregnancies with a complaint of fluid leakage are enrolled in the study. Prior to speculum examination, sagittal view of the birth canal and transverse view of cervix and fornices are obtained with transperineal technique and images are stored. Then speculum examination for pooling, nitrazine test and placental microglobulin-1 tests are performed and results are recorded. Ultrasound images are analysed by an observer blind to physical examination findings. Hypoechogenic fluid appearance of adequate size around the cervix and in the fornices are considered positive. Placental microglobulin-1 test is used as reference. Sensitivity and specificity values are calculated for each test.